Palo Alto, CANCT03384238Now EnrollingIRB Ready

Pancreatic Adenocarcinoma Clinical Trial in Palo Alto, CA

Access cutting-edge pancreatic adenocarcinoma treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by George Poultsides

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access pancreatic adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic adenocarcinoma treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this pancreatic adenocarcinoma clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Pancreatic Adenocarcinoma Study in Palo Alto

This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.

Sponsor: George Poultsides

Who Can Participate

Inclusion Criteria

Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma
Planned standard of care surgery with curative intent for pancreatic adenocarcinoma
Life expectancy of more than 12 weeks
Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level =\< 1
Hemoglobin \>= 9 gm/dL
Platelet count \>= 100,000/mm\^3
Magnesium \> the lower limit of normal per institution normal lab values
Potassium \> the lower limit of normal per institution normal lab values
Calcium \> the lower limit of normal per institution normal lab values
Thyroid-stimulating hormone (TSH) \< 13 micro international units/mL

Exclusion Criteria

Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment
History of infusion reactions to panitumumab or other monoclonal antibody therapies
Pregnant or breastfeeding
Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females)
Lab values that in the opinion of the physician would prevent surgical resection
Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT03384238) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Adenocarcinoma Treatment Options in Palo Alto, CA

If you're searching for pancreatic adenocarcinoma treatment options in Palo Alto, CA, this clinical trial (NCT03384238) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in Palo Alto, CA

See all pancreatic cancer clinical trials recruiting in Palo Alto — not just this study.

Browse Pancreatic Cancer Trials in Palo Alto →

Browse More Trials by Condition

Pancreatic Cancer TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA